InNexus Files for Patent Protection of Antibody Production Techniques
March 13, 2008
InNexus Biotechnology has filed for patent protection for certain in vivo recombinant production techniques of its Dynamic Cross Linking antibodies.
The techniques and patents provide significant protection for InNexus’s latest scientific achievement and growing product pipeline.
Thomas Kindt, chief scientific officer of InNexus, said: “The DXLmouse is another R&D tool that enables InNexus to target a desirable antibody, introduce the antibody into the mouse and then have that animal produce the desired antibody incorporating InNexus’s Dynamic Cross Linking technology. Each mouse represents a ‘DXL antibody factory’ which combines the power of natural antibody diversity generation with the augmented potency of DXL technology.”